Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.36 |
| ▸ | ALPP | P05187 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088107 | 0.80 | PDCD1 (0.41) | FFAR1PDCD1CD274TACR1 | |
| SCHEMBL3395701 | 0.79 | PLG (0.39) | CTSAFFAR1 | |
| SCHEMBL3404871 | 0.76 | CTSA (0.37) | CTSAFFAR1TACR1 | |
| SCHEMBL1364563 | 0.74 | LMNA (0.38) | CTSAFFAR1PDCD1CD274 | |
| SCHEMBL3399261 | 0.74 | BRD4 (0.43) | PDCD1CD274 | |
| SCHEMBL3427833 | 0.73 | HTR7 (0.34) | FFAR1PDCD1CD274 | |
| SCHEMBL4095202 | 0.72 | EPHX1 (0.45) | FFAR1PDCD1CD274TACR1 | |
| SCHEMBL4098806 | 0.71 | CHRM3 (0.41) | FFAR1FFAR4PDCD1CD274TACR1 | |
| SCHEMBL4093359 | 0.69 | MAPT (0.42) | TACR1 | |
| SCHEMBL1362144 | 0.68 | CD274 (0.41) | FFAR1FFAR4PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249647-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009100168-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |